Nick M Durham

5PUBLICATIONS
54CO-AUTHORS
NanomedicinePredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 18, 2026
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

|Dec 01, 2022
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Charu Aggarwal, Nabil F Saba, Alain Algazi

|Apr 08, 2022
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.

Lakshmi Nayak, Nathan Standifer, Jorg Dietrich

|Sep 30, 2021
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.

Phillip A Swanson, Marcelino Padilla, Wesley Hoyland

|Jun 27, 2017
GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.

Nick M Durham, Nick Holoweckyj, Randall S MacGill

Pageof 1

Frequent Collaborators

2 joint publications

Emily C Jennings

1 joint publications

Phillip A Swanson

1 joint publications

Kelly McGlinchey

1 joint publications

Paul A Fields